Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Thursday, 10 / 18 / 2018

Articles

Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies

REVIEW ARTICLE

Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies

Heather S. Snyder*1,2, Sami A. Sakaan1,2, Katherine L. March1,2, Osama Siddique3, Rosann Cholankeril4, Carolyn D. Cummings1,2, Chiran Gadiparthi5, Sanjaya K. Satapathy5, Aijaz Ahmed6 and George Cholankeril*5,6

1Department of Pharmacy, Methodist University Hospital, Memphis, TN, USA
2College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA
3Department of Medicine, Memorial Hospital of Rhode Island, Providence, RI, USA
4Roger Williams Medical Center, Providence, RI, USA
5Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, Memphis, TN, USA
6Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA

*Correspondence to: George Cholankeril, Stanford University School of Medicine, 750 Welch Road, Stanford, CA 94304, USA. Tel: +1-914-215-268, Fax: +1-901-516-8178, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. , This email address is being protected from spambots. You need JavaScript enabled to view it. ; Heather S. Snyder, Department of Pharmacy, Methodist University Hospital, 1265 Union Avenue, Memphis, TN 38104, USA. Tel: +1-901-516-9021, Fax: +1-901-516-2412, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2018;6(2):168-174 DOI: 10.14218/JCTH.2017.00050
Received: July 24, 2017 Accepted: January 10, 2018 Published online: March 25, 2018

Abstract

Non-alcoholic fatty liver disease (NAFLD), the most common cause of liver disease, affects approximately 75 to 100 million Americans. Patients with concurrent NAFLD and type 2 diabetes mellitus have a higher risk of progressing to advanced fibrosis and non-alcoholic steatohepatitis compared to non-diabetics. Lifestyle modifications, including weight loss, remain the mainstay of treatment for NAFLD, as there are no medications currently indicated for this disease state. Anti-diabetic pharmacologic therapies aimed at improving insulin sensitivity and decreasing insulin production have been studied to determine their potential role in slowing the progression of NAFLD. In this review, we focus on the evidence surrounding anti-diabetic medications and their ability to improve disease progression in patients with NAFLD.

Keywords

Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Diabetes mellitus

 

 

Journal of Clinical and Translational Hepatology 2018 vol. 6, 168-174  [ Html ] [ PDF Full-text ]

© The Authors 2018. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 logo

You are here: Home